

HIGH TB BURDEN | HIGH HIV BURDEN | HIGH MDR-TB BURDEN

Estimates of TB burden^a 2012

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	44 (43–46)	3.2 (3.1–3.3)
Mortality (HIV+TB only)	1.2 (0.93–1.5)	0.08 (0.07–0.11)
Prevalence (includes HIV+TB)	1 400 (1 200–1 600)	99 (86–113)
Incidence (includes HIV+TB)	1 000 (880–1 100)	73 (64–82)
Incidence (HIV+TB only)	7.3 (6.4–8.2)	0.53 (0.47–0.6)
Case detection, all forms (%)	89 (79–100)	

TB case notifications 2012

NEW CASES (%)	RETREATMENT CASES (%)
Smear-positive 316 332 (37)	Relapse 31 784 (76)
Smear-negative 533 977 (62)	Treatment after failure 2 281 (5)
Smear-unknown / not done 2 073 (<1)	Treatment after default 738 (2)
Extrapulmonary 6 479 (<1)	Other 7 014 (17)
Other 0 (0)	
Total new 858 861	Total retreatment 41 817
Other (history unknown) 0	
Total new and relapse 890 645	Total cases notified 900 678

New cases

	SMEAR-POSITIVE	SMEAR-NEGATIVE/ UNKNOWN/ NOT DONE	EXTRAPULMONARY
M:F ratio	2.5	2.1	0.8
Age < 15	1 091	4 288	246

Laboratories

Smear (per 100 000 population)	0.2
Culture (per 5 million population)	3.7
Drug susceptibility testing (per 5 million population)	0.7
Is second-line drug susceptibility testing available?	Yes, in country

Treatment success rate 2011 (%)

New smear-positive and/or culture-positive	95
New smear-negative/extrapulmonary	95
Retreatment	90
Is rifampicin used throughout treatment for new patients?	Yes

TB/HIV 2012

	NUMBER	(%)
TB patients with known HIV status ^b	309 385	(34)
HIV-positive TB patients	5 866	(2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)	3 454	(59)
HIV-positive people screened for TB	294 795	
HIV-positive people provided with IPT		

Estimates of MDR-TB burden 2012^a

	NEW	RETREATMENT
% of TB cases with MDR-TB	5.7 (4.5–7)	26 (22–30)
MDR-TB cases among notified pulmonary TB cases	49 000 (38 000–60 000)	11 000 (9 000–12 000)

Reported cases of MDR-TB 2012

	NEW	RETREATMENT	TOTAL
Cases tested for MDR-TB	11 472 (4%)	4 861 (12%)	16 333
Laboratory-confirmed MDR-TB cases	826	1 678	3 007
Patients started on MDR-TB treatment			1 906

Financing TB control

National TB programme budget (US\$ millions)	359
% Funded domestically	74%
% Funded internationally	11%
% Unfunded	15%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

^a Ranges represent uncertainty intervals.

